# Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

> **NCT05156398** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 640 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05156398
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-28
- **Primary completion:** 2031-11-29
- **Final completion:** 2032-11-27
- **Target enrollment:** 640 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156398, "Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05156398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*